Citadel Advisors’s Achieve Life Sciences ACHV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-24,718
| Closed | -$67.8K | – | 12632 |
|
|
2025
Q2 | $55.9K | Buy |
24,718
+18,495
| +297% | +$52.7K | ﹤0.01% | 11718 |
|
|
2025
Q1 | $16.6K | Sell |
6,223
-25,512
| -80% | -$79.3K | ﹤0.01% | 13274 |
|
|
2024
Q4 | $112K | Buy |
31,735
+31,729
| +528,817% | +$144K | ﹤0.01% | 11302 |
|
|
2024
Q3 | $28 | Buy |
+6
| New | +$27 | ﹤0.01% | 14109 |
|
|
2023
Q4 | – | Sell |
-6,787
| Closed | -$29.2K | – | 14168 |
|
|
2023
Q3 | $29.2K | Sell |
6,787
-7,902
| -54% | -$39.8K | ﹤0.01% | 12292 |
|
|
2023
Q2 | $76.2K | Buy |
14,689
+12,196
| +489% | +$85.5K | ﹤0.01% | 11292 |
|
|
2023
Q1 | $17K | Sell |
2,493
-48,253
| -95% | -$229K | ﹤0.01% | 13179 |
|
|
2022
Q4 | $125K | Buy |
50,746
+15,746
| +45% | +$40.4K | ﹤0.01% | 10880 |
|
|
2022
Q3 | $116K | Buy |
35,000
+21,725
| +164% | +$104K | ﹤0.01% | 10959 |
|
|
2022
Q2 | $65K | Buy |
+13,275
| New | +$90K | ﹤0.01% | 11756 |
|
|
2022
Q1 | – | Sell |
-19,207
| Closed | -$143K | – | 13457 |
|
|
2021
Q4 | $149K | Buy |
+19,207
| New | +$151K | ﹤0.01% | 12262 |
|
|
2021
Q2 | – | Sell |
-12,456
| Closed | -$144K | – | 13575 |
|
|
2021
Q1 | $144K | Buy |
+12,456
| New | +$148K | ﹤0.01% | 12093 |
|
|
2020
Q2 | – | Sell |
-7,011
| Closed | -$46K | – | 9691 |
|
|
2020
Q1 | $46K | Buy |
+7,011
| New | +$67.8K | ﹤0.01% | 9061 |
|
|
2019
Q3 | – | Sell |
-718
| Closed | -$28K | – | 9086 |
|
|
2019
Q2 | $28K | Sell |
718
-113
| -14% | -$7.99K | ﹤0.01% | 8885 |
|
|
2019
Q1 | $54K | Buy |
+831
| New | +$33.6K | ﹤0.01% | 8789 |
|
|
2018
Q4 | – | Sell |
-1,329
| Closed | -$84K | – | 9007 |
|
|
2018
Q3 | $84K | Buy |
+1,329
| New | +$84.1K | ﹤0.01% | 8639 |
|
|
2017
Q4 | – | Sell |
-55
| Closed | -$22K | – | 7913 |
|
|
2017
Q3 | $22K | Buy |
55
+27
| +96% | +$19.4K | ﹤0.01% | 7337 |
|
|
2017
Q2 | $22K | Buy |
28
+18
| +180% | +$14.6K | ﹤0.01% | 7259 |
|
|
2017
Q1 | $9K | Sell |
10
-4
| -29% | -$4.86K | ﹤0.01% | 7339 |
|
|
2016
Q4 | $15K | Buy |
+14
| New | +$13.8K | ﹤0.01% | 7127 |
|
|
2016
Q1 | – | Sell |
-11
| Closed | -$29K | – | 6640 |
|
|
2015
Q4 | $29K | Buy |
+11
| New | +$46.5K | ﹤0.01% | 7680 |
|
|
2015
Q2 | – | Sell |
-16
| Closed | -$75K | – | 8690 |
|
|
2015
Q1 | $75K | Buy |
+16
| New | +$78.6K | ﹤0.01% | 7086 |
|
Other funds holding ACHV
PBM
VCM
SAM
NCM
Citadel Advisors's ACHV Position: Q3 2025 in Review
Citadel Advisors sold out of Achieve Life Sciences (ACHV) in Q3 2025, closing a stake of 24,718 shares — an estimated $67.8K sold.
Citadel Advisors first reported a position in ACHV in Q1 2015 and held it in 22 quarters. The position peaked at $149K in Q4 2021. 66 funds tracked by Wall St. Rank hold ACHV as of Q3 2025.
- Citadel Advisors reported no remaining Achieve Life Sciences position as of Q3 2025 after selling out during the quarter.
- Citadel Advisors sold 24,718 Achieve Life Sciences shares in Q3 2025, an estimated $67.8K.
- Citadel Advisors first reported a position in Achieve Life Sciences in Q1 2015 and held it in 22 quarters.
- Citadel Advisors's Achieve Life Sciences position peaked at $149K in Q4 2021.
- 66 funds tracked by Wall St. Rank held Achieve Life Sciences as of Q3 2025.
Based on Citadel Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.